Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2023 Nov 16

PMID 37973643

Authors

Umme Hani

B H Jaswanth Gowda

Nazima Haider

Kvrns Ramesh

Karthika Paul

Sumel Ashique

Mohammed Gulzar Ahmed

Soumya Narayana

Sourav Mohanto

Prashant Kesharwani

Affiliations

Soon will be listed here.

Abstract

Blood cancer, also known as hematological malignancy, is one of the devastating types of cancer that has significantly paved its mortality mark globally. It persists as an extremely deadly cancer type and needs utmost attention owing to its negligible overall survival rate. Major challenges in the treatment of blood cancer include difficulties in early diagnosis, as well as severe side effects resulting from chemotherapy. In addition, immunotherapies and targeted therapies can be prohibitively expensive. Over the past two decades, scientists have devised a few nanoparticle-based drug delivery systems aimed at overcoming this challenge. These therapeutic strategies are engineered to augment the cellular uptake, pharmacokinetics, and effectiveness of anticancer drugs. However, there are still numerous types of nanoparticles that could potentially improve the efficacy of blood cancer treatment, while also reducing treatment costs and mitigating drug-related side effects. To the best of our knowledge, there has been limited reviews published on the use of nano-based drug delivery systems for the treatment of hematological malignancies. Therefore, we have made a concerted effort to provide a comprehensive review that draws upon recent literature and patents, with a focus on the most promising results regarding the use of nanoparticle-based approaches for the treatment of hematological malignancies. All these crucial points covered under a common title would significantly help researchers and scientists working in the area.

Citing Articles

Sustainable streptomycin-based Ag nanoparticle synthesis and study of the cytotoxicity.

Kakasi B, Varga F, Hopotoszki M, Hopotoszki E, Uddin I Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39909884 DOI: 10.1007/s00210-025-03859-9.

In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?.

Mattioda C, Voena C, Ciardelli G, Mattu C Cells. 2025; 14(1.

PMID: 39791739 PMC: 11720277. DOI: 10.3390/cells14010038.

Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications.

Dastgheib Z, Abolmaali S, Farahavar G, Salmanpour M, Tamaddon A Heliyon. 2024; 10(15):e35655.

PMID: 39170173 PMC: 11336847. DOI: 10.1016/j.heliyon.2024.e35655.

Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks.

Mohammad-Jafari K, Naghib S, Mozafari M Curr Pharm Des. 2024; 30(36):2850-2881.

PMID: 39051580 DOI: 10.2174/0113816128304923240704113319.

New Insights in Psoriasis Management using Herbal Drug Nanocarriers.

Salgaonkar S, Purewal J, Doshi G, Fernandes T, Gharat S, Sawarkar S Curr Pharm Des. 2024; 30(32):2550-2561.

PMID: 39051579 DOI: 10.2174/0113816128330298240708110336.

References

Button E, Chan R, Chambers S, Butler J, Yates P . A systematic review of prognostic factors at the end of life for people with a hematological malignancy. BMC Cancer. 2017; 17(1):213. PMC: 5364562. DOI: 10.1186/s12885-017-3207-7. View

Haloupek N . The Landscape of Blood Cancer Research Today-and Where the Field Is Headed. Blood Cancer Discov. 2021; 1(1):1-4. PMC: 8447268. DOI: 10.1158/2643-3249.BCD-20-0083. View

Khan M, Gowda B, Nasir N, Wahab S, Pichika M, Sahebkar A . Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer. Int J Pharm. 2023; 643:123276. DOI: 10.1016/j.ijpharm.2023.123276. View

Rubnitz J, Gibson B, Smith F . Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010; 24(1):35-63. DOI: 10.1016/j.hoc.2009.11.008. View

Gowda B, Ahmed M, Alshehri S, Wahab S, Vora L, Thakur R . The cubosome-based nanoplatforms in cancer therapy: Seeking new paradigms for cancer theranostics. Environ Res. 2023; 237(Pt 1):116894. DOI: 10.1016/j.envres.2023.116894. View

Dang Y, Guan J . Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med. 2021; 1:10-19. PMC: 8455119. DOI: 10.1016/j.smaim.2020.04.001. View

Zhang D, Liu L, Wang J, Zhang H, Zhang Z, Xing G . Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front Pharmacol. 2022; 13:990505. PMC: 9437283. DOI: 10.3389/fphar.2022.990505. View

Dong N, Liu Z, He H, Lu Y, Qi J, Wu W . "Hook&Loop" multivalent interactions based on disk-shaped nanoparticles strengthen active targeting. J Control Release. 2023; 354:279-293. DOI: 10.1016/j.jconrel.2023.01.022. View

Franiak-Pietryga I, Ostrowska K, Maciejewski H, Ziemba B, Appelhans D, Voit B . Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles. Toxicol Appl Pharmacol. 2018; 357:33-38. DOI: 10.1016/j.taap.2018.08.007. View

10.

Ghosh B, Biswas S . Polymeric micelles in cancer therapy: State of the art. J Control Release. 2021; 332:127-147. DOI: 10.1016/j.jconrel.2021.02.016. View

11.

Wang J, Li S, Han Y, Guan J, Chung S, Wang C . Poly(Ethylene Glycol)-Polylactide Micelles for Cancer Therapy. Front Pharmacol. 2018; 9:202. PMC: 5890116. DOI: 10.3389/fphar.2018.00202. View

12.

Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cantu L . Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. J Control Release. 2021; 332:312-336. DOI: 10.1016/j.jconrel.2021.02.031. View

13.

Lu M, Qiu Q, Luo X, Liu X, Sun J, Wang C . Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents. Asian J Pharm Sci. 2020; 14(3):265-274. PMC: 7032241. DOI: 10.1016/j.ajps.2018.05.011. View

14.

Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A . Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2016; 85:102-112. DOI: 10.1016/j.biopha.2016.11.098. View

15.

Zhang F, Lu Y, Wang M, Zhu J, Li J, Zhang P . Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B. Mol Cell Probes. 2020; 51:101513. DOI: 10.1016/j.mcp.2020.101513. View

16.

Wang M, Qu Y, Hu D, Chen L, Shi K, Jia Y . Methotrexate-loaded biodegradable polymeric micelles for lymphoma therapy. Int J Pharm. 2018; 557:74-85. DOI: 10.1016/j.ijpharm.2018.12.025. View

17.

Varela-Moreira A, van Straten D, van Leur H, Ruiter R, Deshantri A, Hennink W . Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model. Int J Pharm X. 2020; 2:100049. PMC: 7262453. DOI: 10.1016/j.ijpx.2020.100049. View

18.

Deshantri A, Fens M, Ruiter R, Metselaar J, Storm G, van Bloois L . Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. J Control Release. 2019; 296:232-240. DOI: 10.1016/j.jconrel.2019.01.028. View

19.

Li Z, Guo D, Yin X, Ding S, Shen M, Zhang R . Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C/Apaf-1/Caspase-9/Caspase-3 signaling pathway in vitro. Biomed Pharmacother. 2020; 122:109712. DOI: 10.1016/j.biopha.2019.109712. View

20.

Zeinabad H, Yeoh W, Arif M, Lomora M, Banz Y, Riether C . Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells. Biomaterials. 2023; 298:122126. DOI: 10.1016/j.biomaterials.2023.122126. View